A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs BG 00011 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms SPIRIT
- Sponsors Biogen
- 18 Nov 2019 Planned End Date changed from 29 Nov 2019 to 2 Dec 2019.
- 18 Nov 2019 Planned primary completion date changed from 29 Nov 2019 to 2 Dec 2019.
- 13 Sep 2019 Status changed from recruiting to discontinued; the safety follow ups and end-of-study visits are in progress.